Show simple item record

dc.contributor.authorHickish, T
dc.contributor.authorAndre, T
dc.contributor.authorWyrwicz, L
dc.contributor.authorSaunders, Mark P
dc.contributor.authorSarosiek, T
dc.contributor.authorKocsis, J
dc.contributor.authorNemecek, R
dc.contributor.authorRogowski, W
dc.contributor.authorLesniewski-Kmak, K
dc.contributor.authorPetruzelka, L
dc.contributor.authorApte, R
dc.contributor.authorMohanty, P
dc.contributor.authorStecher, M
dc.contributor.authorSimard, J
dc.contributor.authorde Gramont, A
dc.date.accessioned2017-03-04T18:29:52Z
dc.date.available2017-03-04T18:29:52Z
dc.date.issued2017-02
dc.identifier.citationMABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study. 2017, 18(2):192-201 Lancet Oncolen
dc.identifier.issn1474-5488
dc.identifier.pmid28094194
dc.identifier.doi10.1016/S1470-2045(17)30006-2
dc.identifier.urihttp://hdl.handle.net/10541/620166
dc.description.abstractMABp1, an antibody that targets interleukin 1α, has been associated with antitumour activity and relief of debilitating symptoms in patients with advanced colorectal cancer. We sought to establish the effect of MABp1 with a new primary endpoint in patients with advanced colorectal cancer.
dc.language.isoenen
dc.rightsArchived with thanks to The Lancet. Oncologyen
dc.titleMABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study.en
dc.typeArticleen
dc.contributor.departmentPoole Hospital NHS Foundation Trust, Poole, Dorset, UKen
dc.identifier.journalThe Lancet Oncologyen
html.description.abstractMABp1, an antibody that targets interleukin 1α, has been associated with antitumour activity and relief of debilitating symptoms in patients with advanced colorectal cancer. We sought to establish the effect of MABp1 with a new primary endpoint in patients with advanced colorectal cancer.


Files in this item

This item appears in the following Collection(s)

Show simple item record